Is Beta-Blocker Use Beneficial in Breast Cancer? A Meta-Analysis

@article{Kim2017IsBU,
  title={Is Beta-Blocker Use Beneficial in Breast Cancer? A Meta-Analysis},
  author={Hyun Yul Kim and Younglae Jung and Sang Hyup Lee and Hyuk Jae Jung and Kyoungjune Pak},
  journal={Oncology},
  year={2017},
  volume={92},
  pages={264 - 268}
}
Objective: Preclinical studies have proved that beta-blocking agents inhibit several pathways for breast cancer progression and metastasis. We aimed to evaluate the association between beta-blocker use and prognosis of breast cancer. Methods: A systematic search for studies from MEDLINE and EMBASE (inception to March 2014) was performed using the keywords “breast cancer” and “beta-blocker.” In 2 groups of breast cancer patients (beta-blocker users and non-beta-blocker users), overall deaths… 

Figures and Tables from this paper

Beta-blocker use is not associated with improved clinical outcomes in women with breast cancer: a meta-analysis

TLDR
Current evidence from observational studies does not support a significant association between beta-blocker use and improved prognosis in women with breast cancer.

β-Blocker use is not associated with improved clinical outcomes in women with breast cancer: a meta-analysis

TLDR
Current evidence from observational studies does not support a significant association between BB use and improved prognosis in women with breast cancer.

Effect of beta-blockers on survival of lung cancer patients: a systematic review and meta-analysis

TLDR
The authors' findings do not suggest an overall survival advantage in patients with lung cancer using beta-blocker therapy when compared to non-users, and further prospective cohort studies are warranted to definitively clarify any possible beneficial effect of beta- blockers on lung cancer overall survival.

Beta-Blockers and Cancer: Where Are We?

TLDR
Overall, data suggest that propranolol may be used as a complement for the treatment of several types of cancer due to its ability to improve cancer outcomes by decreasing cancer cell proliferation rates.

Angiotensin Receptor Blockers Associated with Improved Breast Cancer Survival—A Nationwide Cohort Study from Finland

TLDR
Only ATR-blockers were associated with improved breast cancer survival in both prediagnostic and postdiagnostic use, and the association was dose dependent and supported by a biological rationale as a causal explanation.

Use of Antihypertensive Medications and Survival of Breast, Colorectal, Lung, or Stomach Cancer.

TLDR
Ass associations of common antihypertensive medications with overall survival and disease-specific survival with comprehensive adjustment for potential confounding factors are examined to suggest angiotensin II receptor blockers, beta-adrenergic receptor blockers and calcium channel blockers may be associated with improved survival outcomes of gastrointestinal cancers.

A narrative review on the interaction between genes and the treatment of hypertension and breast cancer

Objective The aim to discuss the close relationship between the common biological mechanisms of breast cancer and hypertension, inflammation and oxidative stress, breast cancer gene mutations breast

Beta blockade as adjunctive breast cancer therapy: A review.

References

SHOWING 1-10 OF 23 REFERENCES

Beta blockers and breast cancer mortality: a population- based study.

TLDR
Evidence in humans is provided to support preclinical observations suggesting that inhibiting the β₂-adrenergic signaling pathway can reduce breast cancer progression and mortality.

Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival.

TLDR
This proof-of-principle study showed beta-blocker therapy significantly reduces distant metastases, cancer recurrence, and cancer-specific mortality in breast cancer patients suggesting a novel role for beta- blocker therapy.

Beta blockers and angiotensin-converting enzyme inhibitors’ purported benefit on breast cancer survival may be explained by aspirin use

TLDR
The strong protective association with aspirin use confounds the associations with these other drugs and underscores the importance of considering aspirin use in analyses of breast cancer survival.

Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort

TLDR
Observational data from the LACE Study cohort suggest that BC recurrence and survival were associated with exposure to two commonly used classes of anti-hypertensive medications and greater attention should focus on the potential role of these commonly used medications in BC outcomes.

Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer.

TLDR
BB intake was associated with improved RFS in all patients with breast cancer and in patients with TNBC, and additional studies evaluating the potential benefits of beta-adrenergic blockade on breast cancer recurrence are warranted.

Beta-blocker usage and breast cancer survival: a nested case-control study within a UK clinical practice research datalink cohort.

TLDR
There was little evidence of an association between post-diagnostic beta-blocker usage and breast cancer progression and further studies which include information on tumour receptor status are warranted to determine whether response to Beta-blockers varies by tumour subtypes.

Stress Hormone–Mediated Invasion of Ovarian Cancer Cells

TLDR
These findings provide direct experimental evidence that stress hormones can enhance the invasive potential of ovarian cancer cells and are most likely mediated by stimulation of MMPs.

Functional beta-adrenergic receptors in breast cancer cells.

Using L-[3H]dihydroalprenolol [( 3H]DHA), a potent beta-adrenergic antagonist, we demonstrated in breast cancer cells the presence of beta-adrenergic receptors with high affinity (Kd 1-9 nM) as shown

Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs

TLDR
induced migration, using MDA‐MB‐468 breast and PC‐3 prostate carcinoma cells, can be inhibited by using specific, clinically established receptor antagonists to the β2‐adrenoceptor, the D2 receptor, or the neurokinin‐1 receptor, respectively.